Schmitz G - Search Results

1

Efficacy of lipid reduction with DALI and MONET.

Ramlow W, Röseler E, Heigl F, Spitthöver R, Ringel J, Schmitz G, Heinzler R, Abdul-Rahman N, Leistikow F, Himmelsbach F, Schettler V, Pham J, Kozik-Jaromin J. Ramlow W, et al. Among authors: schmitz g. Atheroscler Suppl. 2017 Nov;30:217-224. doi: 10.1016/j.atherosclerosissup.2017.05.035. Epub 2017 Jun 1. Atheroscler Suppl. 2017. PMID: 29096841

2

Safety aspects of lipidapheresis using DALI and MONET - Multicenter observational study.

Kozik-Jaromin J, Röseler E, Heigl F, Spitthöver R, Ringel J, Schmitz G, Heinzler R, Abdul-Rahman N, Leistikow F, Himmelsbach F, Schettler V, Uhlenbusch-Körwer I, Ramlow W. Kozik-Jaromin J, et al. Among authors: schmitz g. Atheroscler Suppl. 2017 Nov;30:225-231. doi: 10.1016/j.atherosclerosissup.2017.05.036. Atheroscler Suppl. 2017. PMID: 29096842

3

Familial hypercholesterolemia and lipoprotein(a) hyperlipidemia as independent and combined cardiovascular risk factors.

Orsó E, Ahrens N, Kilalić D, Schmitz G. Orsó E, et al. Among authors: schmitz g. Atheroscler Suppl. 2009 Dec 29;10(5):74-8. doi: 10.1016/S1567-5688(09)71816-1. Atheroscler Suppl. 2009. PMID: 20129380 Review.

4

Acute effects of lipid apheresis on human serum lipidome.

Tselmin S, Schmitz G, Julius U, Bornstein SR, Barthel A, Graessler J. Tselmin S, et al. Among authors: schmitz g. Atheroscler Suppl. 2009 Dec 29;10(5):27-33. doi: 10.1016/S1567-5688(09)71806-9. Atheroscler Suppl. 2009. PMID: 20129370

5

Lipoprotein(a) hyperlipidemia as cardiovascular risk factor: pathophysiological aspects.

Schmitz G, Orsó E. Schmitz G, et al. Clin Res Cardiol Suppl. 2015 Apr;10(Suppl 1):21-5. doi: 10.1007/s11789-015-0074-0. Clin Res Cardiol Suppl. 2015. PMID: 25708587 Free PMC article.

6

A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease.

Rothe G, Herr AS, Stöhr J, Abletshauser C, Weidinger G, Schmitz G. Rothe G, et al. Among authors: schmitz g. Atherosclerosis. 1999 May;144(1):251-61. doi: 10.1016/s0021-9150(99)00061-1. Atherosclerosis. 1999. PMID: 10381298 Clinical Trial.

7

Apolipoprotein AI and HDL(3) inhibit spreading of primary human monocytes through a mechanism that involves cholesterol depletion and regulation of CDC42.

Diederich W, Orsó E, Drobnik W, Schmitz G. Diederich W, et al. Among authors: schmitz g. Atherosclerosis. 2001 Dec;159(2):313-24. doi: 10.1016/s0021-9150(01)00518-4. Atherosclerosis. 2001. PMID: 11730811

8

[Classification of hyperlipoproteinemias and interpretation of laboratory parameters].

Herrmann W, Lackner KJ, Schmitz G. Herrmann W, et al. Among authors: schmitz g. Wien Med Wochenschr. 1994;144(12-13):292-9. Wien Med Wochenschr. 1994. PMID: 8650932 Review. German.

9

Screening for functional sequence variations and mutations in ABCA1.

Probst MC, Thumann H, Aslanidis C, Langmann T, Buechler C, Patsch W, Baralle FE, Dallinga-Thie GM, Geisel J, Keller C, Menys VC, Schmitz G. Probst MC, et al. Among authors: schmitz g. Atherosclerosis. 2004 Aug;175(2):269-79. doi: 10.1016/j.atherosclerosis.2004.02.019. Atherosclerosis. 2004. PMID: 15262183

10

Changes in HDL-associated apolipoproteins relate to mortality in human sepsis and correlate to monocyte and platelet activation.

Barlage S, Gnewuch C, Liebisch G, Wolf Z, Audebert FX, Glück T, Fröhlich D, Krämer BK, Rothe G, Schmitz G. Barlage S, et al. Among authors: schmitz g. Intensive Care Med. 2009 Nov;35(11):1877-85. doi: 10.1007/s00134-009-1609-y. Epub 2009 Aug 8. Intensive Care Med. 2009. PMID: 19669126

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,002 results

Search Page

Filters